help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 6, 2009
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2009-1479
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
94/11/4367    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Gaal, J.
Right arrow Articles by de Krijger, R. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaal, J.
Right arrow Articles by de Krijger, R. R.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Cardiovascular Endocrinology
Right arrow Endocrine Oncology

Submitted on July 10, 2009
Accepted on August 21, 2009

Parasympathetic Paragangliomas Are Part of the Von Hippel-Lindau Syndrome

José Gaal*, Francien H. van Nederveen, Zoran Erlic, Esther Korpershoek, Rogier Oldenburg, Carsten C. Boedeker, Udo Kontny, Hartmut P. Neumann, Winand N. M. Dinjens, and Ronald R. de Krijger

Department of Pathology (J.G., F.H.v.N., E.K., W.N.M.D., R.d.K.), Josephine Nefkens Institute, and Department of Clinical Genetics (R.O.), Erasmus MC, University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; and Department of Nephrology (Z.E., H.P.N.), Section of Preventive Medicine, and Departments of Otorhinolaryngology (C.C.B.) and Pediatric Oncology (U.K.), Albert-Ludwigs-University, D 79106 Freiburg, Germany

* To whom correspondence should be addressed. E-mail: j.gaal{at}erasmusmc.nl.

Context: Von Hippel-Lindau (VHL) disease, caused by germline mutations in the VHL gene, is a hereditary tumor syndrome manifested by hemangioblastomas, clear cell renal cell carcinomas, and pheochromocytomas. In addition, a multitude of other rare tumors, including parasympathetic paragangliomas, can occur and even be the sole manifestation of VHL disease. The VHL gene is a bona fide tumor suppressor gene with biallelic inactivation contributing to tumor formation. However, in parasympathetic paragangliomas occurring in VHL disease, biallelic inactivation of the VHL gene has not been demonstrated to date.

Design: The head and neck paragangliomas of two VHL patients were analyzed for mutations by direct sequencing of the VHL gene. In addition loss of heterozygosity analysis was performed for three microsatellite loci near the VHL gene. To rule out other underlying genetic causes of the parasympathetic paragangliomas, mutation analysis of the SDHB, SDHC, and SDHD genes was also performed.

Results: Apart from germline VHL mutations, no additional mutations were found in the paraganglioma-related tumor suppressor genes SDHB, SDHC, and SDHD. Analysis of paraganglioma tissue revealed loss of the VHL wild-type allele in both tumors, indicating that in these tumors biallelic VHL gene inactivation occurred.

Conclusions: These findings indicate that parasympathetic paragangliomas in VHL disease, although rare, are part of the syndrome and related to VHL gene inactivation. Clinicians should be aware of the potential occurrence of parasympathetic paragangliomas in VHL disease.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society